 |
市場調査レポート
商品コード
1441268
がん支持療法薬の世界市場規模、シェア、成長分析、タイプ別、用途別-産業予測、2023～2030年Global Cancer Supportive Care Drugs Market Size, Share, Growth Analysis, By Type(ESA (Erythropoiesis-Stimulating Agents), G-CSFs (Granulocyte Colony-Stimulating Factors)), By Application(Breast Cancer, Lung Cancer) - Industry Forecast 2023-2030 |
||||||
| がん支持療法薬の世界市場規模、シェア、成長分析、タイプ別、用途別-産業予測、2023～2030年 |
|
出版日: 2024年02月19日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
がん支持療法薬の世界市場規模は2022年に883億米ドルと評価され、2023年の942億2,000万米ドルから2031年には1,582億9,000万米ドルに成長し、予測期間中（2024～2031年）のCAGRは6.70％で成長する展望です。
がん支持療法薬の世界市場は、がん治療の副作用を緩和し、がん患者の全体的な生活の質を向上させるのに役立っています。化学療法、放射線療法、標的治療などの治療法は、しばしば衰弱させる副作用をもたらすため、支持療法薬は症状管理に不可欠です。この市場は、がん罹患率の上昇、高齢者人口の増加、がん治療法の進歩などの要因によって大幅に拡大しています。支持療法薬は、制吐剤、鎮痛剤、造血剤など多様な医薬品を含み、治療の副作用を軽減することを目的としています。継続的な研究開発の努力は、より正確で効果的な支持療法を生み出すことに集中しています。製薬会社は、がん治療と支持療法薬を統合した包括的な治療オプションを提供するために協力しています。がん治療法の進歩により、支持療法薬の需要がさらに高まると予想されます。市場成長の主要促進要因としては、患者中心のアプローチや、治療中の患者の健康維持の重要性に対する意識の高まりが挙げられます。治療に関連する副作用を標的とし、患者の快適性を高める革新的な治療法の開発が進んでいることは、世界のがん支持療法薬市場の将来像を形成する上で極めて重要な役割を果たすと思われます。
目次
エグゼクティブサマリー
- 市場概要
- 繁栄と衰退
調査手法
- 情報調達
- セカンダリとプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資の分析
- 主要成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
がん支持療法薬の世界市場：タイプ別
- 市場概要
- ESA（赤血球生成刺激剤）
- G-CSF（顆粒球コロニー刺激因子）
- 制吐薬
- ビスホスホネート
- オピオイド
- NSAID（非ステロイド性自己炎症薬）
- その他
がん支持療法薬の世界市場：用途別
- 市場概要
- 乳がん
- 肺がん
- 結腸直腸がん
- 前立腺がん
- 肝臓がん
- 胃がん
- その他
がん支持療法薬の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Amgen Inc.（米国）
- Johnson & Johnson（米国）
- Roche Holding AG（スイス）
- Amneal Pharmaceuticals LLC（米国）
- Novartis AG（スイス）
- Pfizer Inc.（米国）
- Mylan N.V.（米国）
- Bristol Myers Squibb（米国）
- Merck & Co., Inc.（米国）
- Ipsen Pharma（フランス）
- Eli Lilly and Company（米国）
- Teva Pharmaceutical Industries Ltd.（イスラエル）
- Helsinn Healthcare SA（スイス）
- GlaxoSmithKline plc（英国）
- F. Hoffmann-La Roche Ltd.（スイス）
- Takeda Pharmaceutical Company Limited（日本）
- Eisai Co., Ltd.（日本）
- Astellas Pharma Inc.（日本）
- Mundipharma International Limited（英国）
- Sanofi（フランス）
- Bayer AG（ドイツ）
- AstraZeneca plc（英国）
- Kyowa Kirin Co., Ltd.（日本）
- Dr. Reddy's Laboratories Ltd.（インド）
- Sun Pharmaceutical Industries Ltd.（インド）
Global Cancer Supportive Care Drugs Market size was valued at USD 88.3 billion in 2022 and is poised to grow from USD 94.22 billion in 2023 to USD 158.29 billion by 2031, growing at a CAGR of 6.70% during the forecast period (2024-2031).
The global market for cancer supportive care drugs is instrumental in alleviating the adverse effects of cancer treatments and improving the overall quality of life for cancer patients. Therapies like chemotherapy, radiation, and targeted treatments often bring about debilitating side effects, making supportive care drugs indispensable for symptom management. This market has experienced substantial expansion driven by factors such as rising cancer prevalence, a growing elderly population, and advancements in cancer therapies. Supportive care drugs encompass a diverse range of pharmaceuticals, including antiemetics, analgesics, hematopoietic agents, among others, aiming to mitigate treatment side effects. Continuous research and development efforts are focused on creating more precise and efficacious supportive care therapies. Pharmaceutical companies are collaborating to offer comprehensive treatment options integrating cancer therapies with supportive care drugs. Anticipated advancements in cancer treatment methods are expected to further drive the demand for supportive care drugs. Key drivers of the market's growth include a patient-centric approach and increased awareness of the importance of maintaining patient well-being during treatment. The ongoing development of innovative therapies targeting treatment-related side effects and enhancing patient comfort will play a pivotal role in shaping the future landscape of the global cancer supportive care drugs market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Supportive Care Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cancer Supportive Care Drugs Market Segmental Analysis
By Type, the market is segmented into ESA (Erythropoiesis-Stimulating Agents), G-CSFs (Granulocyte Colony-Stimulating Factors), Antiemetics, Bisphosphonates, Opioids, NSAIDs (Non-Steroidal Auto Inflammatory Drugs), Others. By Application, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer, Others. By distribution channel, the market is segmented into Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Cancer Supportive Care Drugs Market
The escalating worldwide incidence of cancer underscores the growing necessity for cancer supportive care medications. As more individuals undergo treatments such as chemotherapy, radiation therapy, and targeted therapies, the demand intensifies for managing the adverse effects associated with these interventions. Supportive care drugs play a crucial role in enhancing patients' quality of life by alleviating symptoms such as nausea, pain, anemia, and fatigue, thereby providing significant relief throughout their cancer treatment journey.
Restraints in the Global Cancer Supportive Care Drugs Market
The complex process of approving cancer supportive drugs stems from the necessity for rigorous clinical trials to ascertain their safety and efficacy. This intricate approval procedure, governed by regulatory barriers and stringent development and marketing guidelines, often leads to delays in introducing new medications to the market. Consequently, patients encounter challenges accessing innovative supportive care options, thereby limiting their treatment choices.
Market Trends of the Global Cancer Supportive Care Drugs Market
With the evolving landscape of cancer treatments tailored to individual patients, there's a growing recognition of the importance of personalized supportive care. This approach acknowledges the unique characteristics of each patient's cancer type, treatment regimen, and health status, leading to the development of specialized drugs to mitigate specific side effects and symptoms such as chemotherapy-induced nausea, vomiting, fatigue, and anemia. By enhancing the quality of life for patients and promoting treatment adherence, personalized supportive care not only addresses the challenges of cancer treatment but also enhances overall outcomes.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Cancer Supportive Care Drugs Market by Type
- Market Overview
- ESA (Erythropoiesis-Stimulating Agents)
- G-CSFs (Granulocyte Colony-Stimulating Factors)
- Antiemetics
- Bisphosphonates
- Opioids
- NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
- and Others
Global Cancer Supportive Care Drugs Market by Application
- Market Overview
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
- Stomach Cancer
- and Others
Global Cancer Supportive Care Drugs Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amneal Pharmaceuticals LLC (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Helsinn Healthcare SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mundipharma International Limited (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kyowa Kirin Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
